ly stable and apyrexial. Clinically, there was no palpable lymphadenopathy, and examination of the abdomen showed no evidence of hepatosplenomegaly. Chest auscultation revealed normal heart sounds and bibasal fine inspiratory crepitations. Current medications at the time of admission were hydroxychloroquine 200 mg daily, omeprazole, and ferrous fumarate.
Blood tests on admission revealed significant neutropenia with white cell count of 2.0×10 9 /L, neutrophil count of 0.10×10 9 /L, Hb level of 116 g/dL, and platelet count of 401×10 9 /L. Renal and liver functions, and bone profile were normal, but the C-reactive protein level was elevated at 86. Urine dip and blood cultures were negative. Both chest X-ray and abdominal X-rays done at the time of admission were unremarkable. An abdominal ultrasound done a few days after admission did not show any lymphadenopathy or hepatosplenomegaly.
Hydroxychloroquine was stopped on admission because of concerns regarding agranulocytosis, and she was monitored for sepsis. After 24 h, was discharged home. The neutrophil count was noted to return to normal within days of stopping hydroxychloroquine. A diagnosis of hydroxychloroquine-induced agranulocytosis was made.
Discussion
Agranulocytosis is still considered a rare complication of treatment with hydroxychloroquine (2) . A detailed literature search uncovered only a few past case reports detailing this particular side effect with hydroxychloroquine, and none gave the incidence for such an occurrence. However, other severe blood dyscrasias including leukopenia, aplastic anemia, and thrombocytopenia, have also been linked to hydroxychloroquine use (3). Mild leukopenia has been more frequently observed with cases of prolonged use of chloroquines, with one study giving an incidence of 4.8% (4). In the case reports found, all the patients appear to have been on hydroxychloroquine for several months before developing agranulocytosis, as in our case (2) . In all cases, recovery from agranulocytosis followed after the discontinuation of hydroxychloroquine.
The clinical findings in this case and investigations help support a diagnosis of drug-induced agranulocytosis. As mentioned, there was no evidence of sepsis, which is a known cause of the development of neutropenia in otherwise healthy patients, and viral studies were all negative. Although the patient in this case did not undergo bone marrow sampling, in other case studies where this was done, the sampled bone marrow was normal or only showed minor irregularities of white cell counts (2, 4). In the past, immune mechanisms have also been considered as a cause of this reaction. However, previous case studies have not found any evidence of pre-existing leukocyte autoantibodies, and Coombs tests were negative (5).
The total dose of hydroxychloroquine may be an important mechanism in the development of agranulocytosis (5) . Hydroxychloroquine, like other 4-aminoquinolines (e.g., chloroquine), has a very high volume of distribution and has a slow renal clearance. Consequently, in chronic dosing, hydroxychloroquine has a substantial half-life, with current estimates being between 30 and 60 days, and it is well known to persist in the body for long periods (1, 2) . For this reason, excessive plasma and tissue concentrations of hydroxychloroquine may have been a contributing factor in the development of agranulocytosis in this case.
One possibility that needs to be considered is the potential of rituximab to be involved either synergistically or an independent cause of agranulocytosis. Rituximab is a monoclonal antibody against CD20 that causes the lyses of B-lymphocytes (6) . The synergistic effect of rituximab and hydroxychloroquine may have led to the patient developing agranulocytosis, but evidence for this remains to be seen in literature. Rituximab alone has been linked to blood dyscrasias. The increased use of rituximab has uncovered some new latent side effects, namely late-onset neutropenia (6) . This is defined as grade III-IV neutropenia occurring 3-4 weeks after treatment with rituximab. However, such cases are mostly seen in patients on treatment for various lymphomas and not in those with RA. In this case study, the patient had been given only two courses of rituximab, the last infusion being given over 6 weeks previously at the time of the development of agranulocytosis, which reduces the likelihood of rituximab involvement as a cause in this case.
